About alpha teknova inc - TKNO
Alpha Teknova, Inc. engages in the manufacture of cell culture media and supplements. It provides reagents that enable the discovery, development, and production of biopharmaceutical products such as drug therapies, novel vaccines, and molecular diagnostics. Its product offerings include pre-poured media plates for cell growth and cloning, liquid cell culture media and supplements for cellular expansion, and molecular biology reagents for sample manipulation, resuspension, and purification. The company was founded by Thomas E. Davis in 1996 and is headquartered in Hollister, CA.
TKNO At a Glance
Alpha Teknova, Inc.
2451 Bert Drive
Hollister, California 95023
| Phone | 1-831-637-1100 | Revenue | 40.52M | |
| Industry | Pharmaceuticals: Major | Net Income | -17,259,000.00 | |
| Sector | Health Technology | 2025 Sales Growth | 7.352% | |
| Fiscal Year-end | 12 / 2026 | Employees | 158 | |
| View SEC Filings |
TKNO Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 5.016 |
| Price to Book Ratio | 2.959 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -21.815 |
| Enterprise Value to Sales | 5.187 |
| Total Debt to Enterprise Value | 0.135 |
TKNO Efficiency
| Revenue/Employee | 256,455.696 |
| Income Per Employee | -109,234.177 |
| Receivables Turnover | 8.774 |
| Total Asset Turnover | 0.351 |
TKNO Liquidity
| Current Ratio | 4.579 |
| Quick Ratio | 3.643 |
| Cash Ratio | 2.831 |
TKNO Profitability
| Gross Margin | 30.338 |
| Operating Margin | -40.661 |
| Pretax Margin | -42.451 |
| Net Margin | -42.594 |
| Return on Assets | -14.959 |
| Return on Equity | -22.834 |
| Return on Total Capital | -17.785 |
| Return on Invested Capital | -17.098 |
TKNO Capital Structure
| Total Debt to Total Equity | 41.104 |
| Total Debt to Total Capital | 29.13 |
| Total Debt to Total Assets | 25.244 |
| Long-Term Debt to Equity | 38.376 |
| Long-Term Debt to Total Capital | 27.197 |